Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL)
At the request of a group of shareholders which together control not less than one-tenth of all shares in Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), the shareholders are hereby invited to an Extraordinary General Meeting (“EGM”) to be held on Thursday,...Interim report January – June 2023
The Group in summary 01/04/23 01/04/22 01/01/23 01/01/22 Full year -30/06/23 -30/06/22 -30/06/23 -30/06/22 2022 Net sales 1 882 2 612 3 365 3 784 9 684 Operating result...Andreas Andersson steps down as President and CEO. Jonas Sohlman has been appointed acting President and CEO for Intervacc
Stockholm, August 21, 2023 – The Board of Directors for Intervacc AB (publ) (”Intervacc”) has together with Andreas Andersson, made the decision that now is the right time for Andreas Andersson to leave his role as President and CEO, which he has held since late...Intervacc awarded grant to optimise production processes for a fusion protein, which is one component of a prototype vaccine for pigs
Stockholm, August 17, 2023 – Intervacc AB (publ) announces that it has been awarded an “industrial research” grant from Vinnova as part of a project with Testa Center, Uppsala, Sweden, to optimise the manufacturing processes of one component for a prototype...Intervacc to collaborate with Testa Center to optimise production processes for their prototype vaccine for pigs
Stockholm, July 11, 2023 – Intervacc AB (publ) announces the initiation of a project with Testa Center, Uppsala, to optimise the development of manufacturing processes for a prototype vaccine in pigs. Intervacc’s innovative vaccine technology involves fusing...Nyhetstjänster
